Effect of Type II Diabetes Mellitus With Neuropathy on the Clinical Use of Rocuronium

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Effect of Type II Diabetes Mellitus With Neuropathy on the Clinical Use of Rocuronium: A Pharmacodynamic Modelling Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03737942
• Other study ID #: Type II DM with Neuropathy
• Status: Recruiting
• Start date: November 15, 2018
• Est. completion date: March 2019

Study information

• Verified date: November 2018
• Source: Assiut University
• Contact: ghada Abo Elfadl, M.D
• Phone: 01005802086
• Email: ghadafadl77[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

International Diabetes Federation estimates that there are now 415 million adults aged 20-79 with diabetes mellitus worldwide. By 2040 this will rise to 640 million. Although diabetes mellitus is highly prevalent in our environment and one of the most important challenges of modern medicine, only a handful of studies have examined the neuromuscular function in diabetic patients. The shortage of publications in this area is still more surprising if we consider that the neuromuscular blockers are one of the pillars in the administration of general anesthesia. Neuromuscular blockers during surgery are used in tracheal intubation and to improve surgical conditions.

Description:

In diabetic patients, neuropathy, microvascular and macrovascular complications are known clinical findings which require attention during anesthesia. Partial degeneration or segmental demyelination of the nerve fibers and loss of motor units have been reported in patients with diabetes mellitus as well. Therefore, the effects of a neuromuscular blocking agent should be important because of potential complications from incomplete reversal or residual paralysis during anesthesia maintenance. In a series of studies, vecuronium has been the only agent investigated in patients with diabetes mellitus and other diseases characterized by neuromuscular dysfunction. Delayed recovery from the neuromuscular block after vecuronium administration was shown in patients with diabetes mellitus. Currently, rocuronium, with its rapid onset of action, rapid recovery profile and inactive metabolites, is generally known as a safe agent for anesthesia under normal conditions. It is known that the pharmacokinetic properties of rocuronium can be altered in some diseases, such as renal or hepatic failure. However, it has not been investigated whether the effect of rocuronium on neuromuscular function is changed in the presence of neuropathy in diabetes mellitus patients or not. The rationale of our study arises from the finding of many studies that show different changes in the neurophysiological parameters in diabetes mellitus. In diabetic nerve, the conduction velocity of the action potential is decreased, the amplitude of action potentials, both sensory and motor, is smaller, and the latency time is elongated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 2019
• Est. primary completion date: January 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• adult patients aged from 18 years to 65 years.

• scheduled for abdominal surgery under general anesthesia

Exclusion Criteria:

• Patients with allergy to rocuronium

• those diagnosed with diseases that alter neuromuscular blocker response (e.g., Guillain-Barré syndrome, Duchenne type muscle dystrophies, etc.),

• patients receiving treatment with drugs capable of altering neuromuscular transmission or neuromuscular blocker response (e.g., antiseizure drugs, certain antibiotics, etc.).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetic Neuropathies
• Neuromuscular Transmission Disorder

Intervention

Device:
• monitoring of neuromuscular function
started by percutaneous stimulation of the cubital nerve at the wrist level

Locations

Country	Name	City	State
Egypt	Assiut governorate	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Hafeez KR, Tuteja A, Singh M, Wong DT, Nagappa M, Chung F, Wong J. Postoperative complications with neuromuscular blocking drugs and/or reversal agents in obstructive sleep apnea patients: a systematic review. BMC Anesthesiol. 2018 Jul 19;18(1):91. doi: 10.1186/s12871-018-0549-x. — View Citation

Huang L, Chen D, Li S. Streptozotocin diabetes attenuates the effects of nondepolarizing neuromuscular relaxants on rat muscles. Korean J Physiol Pharmacol. 2014 Dec;18(6):461-7. doi: 10.4196/kjpp.2014.18.6.461. Epub 2014 Dec 30. — View Citation

Kashiwai A, Suzuki T, Ogawa S. Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy. Case Rep Anesthesiol. 2012;2012:107952. doi: 10.1155/2012/107952. Epub 2012 Apr 9. — View Citation

Nandi R, Basu SR, Sarkar S, Garg R. A comparison of haemodynamic responses between clinical assessment-guided tracheal intubation and neuromuscular block monitoring-guided tracheal intubation: A prospective, randomised study. Indian J Anaesth. 2017 Nov;61(11):910-915. doi: 10.4103/ija.IJA_93_17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	neuromuscular monitoring	Tetanic stimulus , 50 Hz during 5 seconds (tetanic preconditioning).	before operation,till one hour